Attached files
file | filename |
---|---|
8-K - FORM 8-K - MANNKIND CORP | v57130e8vk.htm |
EX-5.1 - EX-5.1 - MANNKIND CORP | v57130exv5w1.htm |
EX-4.1 - EX-4.1 - MANNKIND CORP | v57130exv4w1.htm |
EX-4.2 - EX-4.2 - MANNKIND CORP | v57130exv4w2.htm |
EX-1.1 - EX-1.1 - MANNKIND CORP | v57130exv1w1.htm |
EX-99.2 - EX-99.2 - MANNKIND CORP | v57130exv99w2.htm |
EX-99.3 - EX-99.3 - MANNKIND CORP | v57130exv99w3.htm |
EX-99.1 - EX-99.1 - MANNKIND CORP | v57130exv99w1.htm |
EXHIBIT 99.4
Risk Factors
RISKS RELATED TO OUR BUSINESS
We depend heavily on the successful development and commercialization of our lead product
candidate, AFREZZA, which is not yet approved, and our other product candidates, which are in early
clinical or preclinical development.
To date, we have not commercialized any product candidates. In March 2009, we submitted an NDA
to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2
diabetes for the control of hyperglycemia. In March 2010, we received a Complete Response letter
regarding this NDA from the FDA. A Complete Response letter is issued by the FDAs Center for Drug
Evaluation and Research when the review of a submitted file is completed and questions remain that
preclude the approval of the NDA in its current form. In July 2010, the FDA accepted our reply to
the Complete Response letter and set a target action date of December 29, 2010. There can be no
assurance that the FDA will find our proposed approach for addressing its questions acceptable. The
FDA could also request that we conduct additional clinical trials to provide sufficient data for
approval of the NDA. There can be no assurance that we will obtain approval of the NDA in a timely
manner or at all.
Our other product candidates are generally in early clinical or preclinical development. We
anticipate that in the near term, our ability to generate revenues will depend solely on the
successful development and commercialization of AFREZZA.
We have expended significant time, money and effort in the development of our lead product
candidate, AFREZZA, which has not yet received regulatory approval and which may not be approved by
the FDA in a timely manner, or at all. We must receive the necessary approvals from the FDA and
similar foreign regulatory agencies before AFREZZA can be marketed and sold in the United States or
elsewhere. Even if we were to receive regulatory approval, we ultimately may be unable to gain
market acceptance of AFREZZA for a variety of reasons, including the treatment and dosage regimen,
potential adverse effects, the availability of alternative treatments and cost effectiveness. If we
fail to commercialize AFREZZA, our business, financial condition and results of operations will be
materially and adversely affected.
We are seeking to develop and expand our portfolio of product candidates through our internal
research programs and through licensing or otherwise acquiring the rights to therapeutics in the
areas of cancer and other indications. All of these product candidates will require additional
research and development and significant preclinical, clinical and other testing prior to seeking
regulatory approval to market them. Accordingly, these product candidates will not be commercially
available for a number of years, if at all.
A significant portion of the research that we are conducting involves new and unproven
compounds and technologies, including AFREZZA, Technosphere platform technology and immunotherapy
product candidates. Research programs to identify new product candidates require substantial
technical, financial and human resources. Even if our research programs identify candidates that
initially show promise, these candidates may fail to progress to clinical development for any
number of reasons, including discovery upon further research that these candidates have adverse
effects or other characteristics that indicate they are unlikely to be effective. In addition, the
clinical results we obtain at one stage are not necessarily indicative of future testing results.
If we fail to successfully complete the development and commercialization of AFREZZA or develop or
expand our other product candidates, or are significantly delayed in doing so, our business and
results of operations will be harmed and the value of our stock could decline.
We have a history of operating losses, we expect to continue to incur losses and we may never
become profitable.
We are a development stage company with no commercial products. All of our product candidates
are still being developed, and all but AFREZZA are still in the early stages of development. Our
product candidates will require significant additional development, clinical trials, regulatory
clearances and additional investment before they can be commercialized. We cannot be certain when
AFREZZA may be approved, or if it will be approved.
We have never been profitable and, as of June 30, 2010, we had incurred a cumulative net loss
of $1.7 billion. The cumulative net loss has resulted principally from costs incurred in our
research and development programs, the write-off of goodwill and general operating expenses. We
expect to make substantial expenditures and to incur increasing operating losses in the future in
order to further develop and commercialize our product candidates, including costs and expenses to
complete clinical trials, seek regulatory approvals and market our product candidates, including
AFREZZA. This cumulative net loss may increase significantly as we continue development and
clinical trial efforts.
Our losses have had, and are expected to continue to have, an adverse impact on our working
capital, total assets and stockholders equity. As of June 30, 2010, we had a stockholders deficit
of $137.7 million. Our ability to achieve and sustain profitability depends upon obtaining
regulatory approvals for and successfully commercializing AFREZZA, either alone or with third
parties. We do not currently have the required approvals to market any of our product candidates,
and we may not receive them. We may not be profitable even if we succeed in commercializing any of
our product candidates. As a result, we cannot be sure when we will become profitable, if at all.
If we fail to raise additional capital our financial condition and business would suffer.
It is costly to develop therapeutic product candidates and conduct clinical trials for these
product candidates. Although we are currently focusing on AFREZZA as our lead product candidate, we
have begun to conduct clinical trials for additional product candidates. Our existing capital
resources will not be sufficient to support the expense of fully commercializing AFREZZA or
developing any of our product candidates.
Based upon our current expectations, we believe that our existing capital resources, including
the loan arrangement with The Mann Group LLC (an entity controlled by our principal stockholder)
but excluding the net proceeds from our recently-completed sale of our 5.75% convertible notes due
2015 and any proceeds to us from our share purchase arrangement with Seaside, will enable us to
continue planned operations through the first quarter of 2011. However, we cannot assure you that
our plans will not change or that changed circumstances will not result in the depletion of our
capital resources more rapidly than we currently anticipate. Accordingly, we may raise additional
funds through the sale of equity or debt securities, the entry into strategic business
collaborations, the establishment of other funding facilities, licensing arrangements and/or assets
sales, in order to continue the development and commercialization of AFREZZA and other product
candidates and to support our other ongoing activities. However, it may be difficult for us to
raise additional funds through the sale of equity or debt securities. As of June 30, 2010, we had a
stockholders deficit of $137.7 million which may raise concerns about our solvency and affect our
ability to raise additional funds. The amount of additional funds we need will depend on a number
of factors, including:
| the rate of progress and costs of our clinical trials and research and development activities, including costs of procuring clinical materials and expanding our own manufacturing facilities; | ||
| our success in establishing strategic business collaborations and the timing and amount of any payments we might receive from any collaboration we are able to establish; | ||
| actions taken by the FDA and other regulatory authorities affecting our products and competitive products; | ||
| our degree of success in commercializing AFREZZA; | ||
| the emergence of competing technologies and products and other adverse market developments; | ||
| the timing and amount of payments we might receive from potential licensees; | ||
| the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights or defending against claims of infringement by others; |
| the costs of discontinuing projects and technologies or decommissioning existing facilities, if we undertake those activities; and | ||
| the costs of performing additional clinical trials to demonstrate safety and efficacy if our current trials do not deliver results sufficient for FDA approval and commercialization. |
We have raised capital in the past primarily through the sale of equity and debt securities.
We may in the future pursue the sale of additional equity and/or debt securities, or the
establishment of other funding facilities. For example, on August 10, 2010, we entered into the
Seaside purchase agreement and the Mann purchase agreement for the sale and issuance by us of up to
36,400,000 shares of our common stock over a period of approximately 50 weeks. Issuances of
additional debt or equity securities or the conversion of any of our currently outstanding
convertible debt securities into shares of our common stock could impact the rights of the holders
of our common stock and may dilute their ownership percentage. Moreover, the establishment of other
funding facilities may impose restrictions on our operations. These restrictions could include
limitations on additional borrowing and specific restrictions on the use of our assets, as well as
prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.
We also may seek to raise additional capital by pursuing opportunities for the licensing or
sale of certain intellectual property and other assets, including our Technosphere technology
platform. We cannot offer assurances, however, that any strategic collaborations, sales of
securities or sales or licenses of assets will be available to us on a timely basis or on
acceptable terms, if at all. We may be required to enter into relationships with third parties to
develop or commercialize products or technologies that we otherwise would have sought to develop
independently, and any such relationships may not be on terms as commercially favorable to us as
might otherwise be the case.
In the event that sufficient additional funds are not obtained through strategic collaboration
opportunities, sales of securities, credit facilities, licensing arrangements and/or asset sales on
a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment
of our projects, including AFREZZA commercialization, or further reduction of costs for facilities
and administration. Moreover, if we do not obtain such additional funds, there will be substantial
doubt about our ability to continue as a going concern and increased risk of insolvency and loss of
investment to the holders of our securities. As of the date hereof, we have not obtained a solvency
opinion or otherwise conducted a valuation of our properties to determine whether our debts exceed
the fair value of our property within the meaning of applicable solvency laws. If we are or become
insolvent, investors in our stock may lose the entire value of their investment.
Deteriorating global economic conditions may have an adverse impact on the loan facility with an
entity controlled by our principal stockholder, which we currently cannot predict.
As widely reported, financial markets in the United States, Europe and Asia have been
experiencing a period of unprecedented turmoil and upheaval characterized by extreme volatility and
declines in security prices, severely diminished liquidity and credit availability, inability to
access capital markets, the bankruptcy, failure, collapse or sale of various financial institutions
and an unprecedented level of intervention from the United States federal government and other
governments. We cannot predict the impact of these events on the loan facility with an entity
controlled by our principal stockholder. If we are unable to draw on this financial resource, our
business and financial condition will be adversely affected.
If we do not achieve our projected development and commercialization goals in the timeframes we
announce and expect, our business would be harmed and the market price of our common stock could
decline.
For planning purposes, we estimate the timing of the accomplishment of various scientific,
clinical, regulatory and other product development goals, which we sometimes refer to as
milestones. These milestones may include the commencement or completion of scientific studies and
clinical trials and the submission of regulatory filings. From time to time, we publicly announce
the expected timing of some of these milestones. All of these milestones are based on a variety of
assumptions. The actual timing of the achievement of these milestones can vary dramatically from
our estimates, in many cases for reasons beyond our control, depending on numerous factors,
including:
| the rate of progress, costs and results of our clinical trial and research and development activities, which will be impacted by the level of proficiency and experience of our clinical staff; | ||
| our ability to identify and enroll patients who meet clinical trial eligibility criteria; | ||
| our ability to access sufficient, reliable and affordable supplies of components used in the manufacture of our product candidates, including insulin and other materials for AFREZZA; | ||
| the costs of expanding and maintaining manufacturing operations, as necessary; | ||
| the extent of scheduling conflicts with participating clinicians and clinical institutions; | ||
| the receipt of approvals by our competitors and by us from the FDA and other regulatory agencies; | ||
| our ability to enter into sales and marketing collaborations for AFREZZA; and | ||
| other actions by regulators. |
In addition, if we do not obtain sufficient additional funds through sales of securities,
strategic collaborations or the license or sale of certain of our assets on a timely basis, we may
be required to reduce expenses by delaying, reducing or curtailing our development of AFREZZA or
other product development activities, which would impact our ability to meet milestones. If we fail
to commence or complete, or experience delays in or are forced to curtail, our proposed clinical
programs or otherwise fail to adhere to our projected development goals in the timeframes we
announce and expect (or within the timeframes expected by analysts or investors), our business and
results of operations will be harmed and the market price of our common stock may decline.
We face substantial competition in the development of our product candidates and may not be able to
compete successfully, and our product candidates may be rendered obsolete by rapid technological
change.
A number of established pharmaceutical companies have or are developing technologies for the
treatment of diabetes. We also face substantial competition for the development of our other
product candidates.
Many of our existing or potential competitors have, or have access to, substantially greater
financial, research and development, production, and sales and marketing resources than we do and
have a greater depth and number of experienced managers. As a result, our competitors may be better
equipped than we are to develop, manufacture, market and sell competing products. In addition,
gaining favorable reimbursement is critical to the success of AFREZZA. Many of our competitors have
existing infrastructure and relationships with managed care organizations and reimbursement
authorities which can be used to their advantage.
The rapid rate of scientific discoveries and technological changes could result in one or more
of our product candidates becoming obsolete or noncompetitive. Our competitors may develop or
introduce new products that render our technology and AFREZZA less competitive, uneconomical or
obsolete. Our future success will depend not only on our ability to develop our product candidates
but to improve them and keep pace with emerging industry developments. We cannot assure you that we
will be able to do so.
We also expect to face increasing competition from universities and other non-profit research
organizations. These institutions carry out a significant amount of research and development in the
areas of diabetes and cancer. These institutions are becoming increasingly aware of the commercial
value of their findings and are more active in seeking patent and other proprietary rights as well
as licensing revenues.
If we fail to enter into a strategic collaboration with respect to AFREZZA, we may not be able to
execute on our business model.
We have held extensive discussions with a number of pharmaceutical companies concerning a
potential strategic business collaboration for AFREZZA. To date we have not reached an agreement
with any of these
companies on a collaboration. We cannot predict when, if ever, we could conclude an agreement
with a partner. There can be no assurance that any such collaboration will be available to us on a
timely basis or on acceptable terms. If we are not able to enter into a collaboration on terms that
are favorable to us, we may be unable to undertake and fund product development, clinical trials,
manufacturing and marketing activities at our own expense. Accordingly, we may have to
substantially reduce our development efforts, which would delay or otherwise impede the
commercialization of AFREZZA.
We will face similar challenges as we seek to develop our other product candidates. Our
current strategy for developing, manufacturing and commercializing our other product candidates
includes evaluating the potential for collaborating with pharmaceutical and biotechnology companies
at some point in the drug development process and for these collaborators to undertake the advanced
clinical development and commercialization of our product candidates. It may be difficult for us to
find third parties that are willing to enter into collaborations on economic terms that are
favorable to us, or at all. Failure to enter into a collaboration with respect to any other product
candidate could substantially increase our requirements for capital and force us to substantially
reduce our development effort.
If we enter into collaborative agreements with respect to AFREZZA and if our third-party
collaborators do not perform satisfactorily or if our collaborations fail, development or
commercialization of AFREZZA may be delayed and our business could be harmed.
We may enter into license agreements, partnerships or other collaborative arrangements to
support the financing, development and marketing of AFREZZA. We may also license technology from
others to enhance or supplement our technologies. These various collaborators may enter into
arrangements that would make them potential competitors. These various collaborators also may
breach their agreements with us and delay our progress or fail to perform under their agreements,
which could harm our business.
If we enter into collaborative arrangements, we will have less control over the timing,
planning and other aspects of our clinical trials, and the sale and marketing of AFREZZA and our
other product candidates. We cannot offer assurances that we will be able to enter into
satisfactory arrangements with third parties as contemplated or that any of our existing or future
collaborations will be successful.
Continued testing of AFREZZA or our other product may not yield successful results, and even if it
does, we may still be unable to commercialize our product.
Our research and development programs are designed to test the safety and efficacy of AFREZZA
and our other product candidates through extensive nonclinical and clinical testing. We may
experience numerous unforeseen events during, or as a result of, the testing process that could
delay or prevent commercialization of AFREZZA or any of our other product candidates, including the
following:
| safety and efficacy results obtained in our nonclinical and initial clinical testing may be inconclusive or may not be predictive of results obtained in later-stage clinical trials or following long-term use, and we may as a result be forced to stop developing product candidates that we currently believe are important to our future; | ||
| the data collected from clinical trials of our product candidates may not be sufficient to support FDA or other regulatory approval; | ||
| after reviewing test results, we or any potential collaborators may abandon projects that we previously believed were promising; and | ||
| our product candidates may not produce the desired effects or may result in adverse health effects or other characteristics that preclude regulatory approval or limit their commercial use if approved. |
Forecasts about the effects of the use of drugs, including AFREZZA, over terms longer than the
clinical trials or in much larger populations may not be consistent with the clinical results. If
use of AFREZZA results in
adverse health effects or reduced efficacy or both, the FDA or other regulatory agencies may
terminate our ability to market and sell AFREZZA, may narrow the approved indications for use or
otherwise require restrictive product labeling or marketing, or may require further clinical
trials, which may be time-consuming and expensive and may not produce favorable results.
As a result of any of these events, we, any collaborator, the FDA, or any other regulatory
authorities, may suspend or terminate clinical trials or marketing of AFREZZA at any time. Any
suspension or termination of our clinical trials or marketing activities may harm our business and
results of operations and the market price of our common stock may decline.
If we are unable to transition successfully from a development company to a company that
commercializes therapeutics, our business would suffer.
We require a well-structured plan to make the transition from the development stage to being a
company with commercial operations. In order to implement our commercialization strategy, we will
need to:
| align our management structure to accommodate the increasing complexity of our operations; | ||
| develop comprehensive and detailed commercialization, clinical development and regulatory plans; and | ||
| implement standard operating procedures. |
If we are unable to accomplish these measures in a timely manner, we would be at considerable
risk of failing to develop the capabilities necessary for commercial operations.
If our suppliers fail to deliver materials and services needed for the production of AFREZZA in a
timely and sufficient manner, or they fail to comply with applicable regulations, our business and
results of operations would be harmed and the market price of our common stock could decline.
For AFREZZA to be commercially viable, we need access to sufficient, reliable and affordable
supplies of insulin, our AFREZZA inhaler, the related cartridges and other materials. We have a
long-term agreement with N.V. Organon for the supply of insulin. In June 2009, we purchased from
Pfizer, a portion of its inventory of bulk insulin and acquired an option to purchase the remainder
of Pfizers insulin inventory, in whole or in part, at a specified price to the extent that Pfizer
has not otherwise disposed of or used the retained insulin.
We obtain FDKP, the precursor raw material for AFREZZA, from a major multinational chemical
manufacturer. We have completed a successful validation campaign of FDKP at commercial scale. We
can also utilize our in-house chemical manufacturing plant for supplemental capacity. We believe
our contract manufacturer has the capacity to supply our current and future commercial
requirements. We obtain our intended commercial AFREZZA inhaler and cartridges from a plastic
molding company located in the United States.
We must rely on our suppliers to comply with relevant regulatory and other legal requirements,
including the production of insulin in accordance with the FDAs current good manufacturing
practices, or cGMP for drug products, and the production of the AFREZZA inhaler and related
cartridges in accordance with Quality System Regulations, or QSR. The supply of any of these
materials may be limited or any of the manufacturers may not meet relevant regulatory requirements,
and if we are unable to obtain any of these materials in sufficient amounts, in a timely manner and
at reasonable prices, or if we should encounter delays or difficulties in our relationships with
manufacturers or suppliers, the development or manufacturing of AFREZZA may be delayed. Any such
events could delay market introduction and subsequent sales of AFREZZA and, if so, our business and
results of operations will be harmed and the market price of our common stock may decline.
We have never manufactured AFREZZA or any other product candidates in commercial quantities, and if
we fail to develop an effective manufacturing capability for our product candidates or to engage
third-party manufacturers with this capability, we may be unable to commercialize these products.
We use our Danbury facility to formulate AFREZZA, fill plastic cartridges with AFREZZA and
blister package the cartridges for use in our clinical trials. This facility has been fully
qualified and undergone inspection by the FDA. The manufacture of pharmaceutical products requires
significant expertise and capital investment, including the development of advanced manufacturing
techniques and process controls. Manufacturers of pharmaceutical products often encounter
difficulties in production, especially in scaling up initial production. These problems include
difficulties with production costs and yields, quality control and assurance and shortages of
qualified personnel, as well as compliance with strictly enforced federal, state and foreign
regulations. If we engage a third-party manufacturer, we would need to transfer our technology to
that third-party manufacturer and gain FDA approval, potentially causing delays in product
delivery. In addition, our third-party manufacturer may not perform as agreed or may terminate its
agreement with us.
Additionally, when we manufacture commercial material on a significantly larger production
scale than the production scale for clinical trial materials, we are required by the FDA to
establish that the results obtained from the clinical trials may reasonably be extrapolated to such
commercial material. We have submitted documentation to the FDA to show correlation to the
clinical-scale production materials but can provide no assurance that approval will be obtained.
Any of these factors could cause us to delay or suspend clinical trials, regulatory
submissions, required approvals or commercialization of our product candidates, entail higher costs
and result in our being unable to effectively commercialize our products. Furthermore, if we or a
third-party manufacturer fail to deliver the required commercial quantities of any product on a
timely basis, and at commercially reasonable prices and acceptable quality, and we were unable to
promptly find one or more replacement manufacturers capable of production at a substantially
equivalent cost, in substantially equivalent volume and quality on a timely basis, we would likely
be unable to meet demand for such products and we would lose potential revenues.
We deal with hazardous materials and must comply with environmental laws and regulations, which can
be expensive and restrict how we do business.
Our research and development work involves the controlled storage and use of hazardous
materials, including chemical, radioactive and biological materials. In addition, our manufacturing
operations involve the use of a chemical that is stable and non-hazardous under normal storage
conditions, but may form an explosive mixture under certain conditions. Our operations also produce
hazardous waste products. We are subject to federal, state and local laws and regulations governing
how we use, manufacture, store, handle and dispose of these materials. Moreover, the risk of
accidental contamination or injury from hazardous materials cannot be completely eliminated, and in
the event of an accident, we could be held liable for any damages that may result, and any
liability could fall outside the coverage or exceed the limits of our insurance. Currently, our
general liability policy provides coverage up to $1 million per occurrence and $2 million in the
aggregate and is supplemented by an umbrella policy that provides a further $4 million of coverage;
however, our insurance policy excludes pollution coverage and we do not carry a separate hazardous
materials policy. In addition, we could be required to incur significant costs to comply with
environmental laws and regulations in the future. Finally, current or future environmental laws and
regulations may impair our research, development or production efforts.
When we purchased the facilities located in Danbury, Connecticut in 2001, there was a soil
cleanup plan in process. As part of the purchase, we obtained an indemnification from the seller
related to the remediation of the soil for all known environmental conditions that existed at the
time the seller acquired the property. The seller is, in turn, indemnified for these known
environmental conditions by the previous owner. We also received an indemnification from the seller
for environmental conditions created during its ownership of the property and for environmental
problems unknown at the time that the seller acquired the property. These additional indemnities
are limited to the purchase price that we paid for the Danbury facilities.
During the construction of our expanded manufacturing facility, we completed the final stages
of the soil cleanup plan in the third quarter of 2008, at a cost of approximately $2.25 million. We
have reached an agreement
with the party responsible for their contribution to past clean-up costs and were reimbursed
$1.625 million in July 2010. The responsible party has agreed to pay for or indemnify us for any
future costs and expenses directly related to the final closure of the environmental remediation.
If we are unable to collect these future costs and expenses, if any, from the responsible party,
our business and results of operations may be harmed.
If we fail to enter into collaborations with third parties, we would be required to establish our
own sales, marketing and distribution capabilities, which could impact the commercialization of our
products and harm our business.
Our products are intended to be used by a large number of healthcare professionals who will
require substantial education and support. For example, a broad base of physicians, including
primary care physicians and endocrinologists, treat patients with diabetes. A large sales force
will be required in order to educate these physicians about the benefits and advantages of AFREZZA
and to provide adequate support for them. Therefore, we plan to enter into collaborations with one
or more pharmaceutical companies to market, distribute and sell AFREZZA, if it is approved. If we
fail to enter into collaborations, we would be required to establish our own direct sales,
marketing and distribution capabilities. Establishing these capabilities can be time-consuming and
expensive and would delay our ability to commercialize AFREZZA. Because we lack experience in
selling pharmaceutical products to the diabetes market, we would be at a disadvantage compared to
our potential competitors, all of whom have substantially more resources and experience than we do.
For example, several other companies selling products to treat diabetes have existing sales forces
in excess of 1,500 sales representatives. We, acting alone, would not initially be able to field a
sales force as large as our competitors or provide the same degree of marketing support. Also, we
would not be able to match our competitors spending levels for pre-launch marketing preparation,
including medical education. We cannot assure you that we will succeed in entering into acceptable
collaborations, that any such collaboration will be successful or, if not, that we will
successfully develop our own sales, marketing and distribution capabilities.
If any product that we may develop does not become widely accepted by physicians, patients,
third-party payers and the healthcare community, we may be unable to generate significant revenue,
if any.
AFREZZA and our other product candidates are new and unproven. Even if any of our product
candidates obtain regulatory approval, they may not gain market acceptance among physicians,
patients, third-party payers and the healthcare community. Failure to achieve market acceptance
would limit our ability to generate revenue and would adversely affect our results of operations.
The degree of market acceptance of AFREZZA and our other product candidates will depend on
many factors, including the:
| claims for which FDA approval can be obtained, including superiority claims; | ||
| perceived advantages and disadvantages of competitive products; | ||
| willingness of the healthcare community and patients to adopt new technologies; | ||
| ability to manufacture the product in sufficient quantities with acceptable quality and cost; | ||
| perception of patients and the healthcare community, including third-party payers, regarding the safety, efficacy and benefits compared to competing products or therapies; | ||
| convenience and ease of administration relative to existing treatment methods; | ||
| pricing and reimbursement relative to other treatment therapeutics and methods; and | ||
| marketing and distribution support. |
Because of these and other factors, any product that we may develop may not gain market acceptance,
which would materially harm our business, financial condition and results of operations.
If third-party payers do not reimburse consumers for our products, our products might not be used
or purchased, which would adversely affect our revenues.
Our future revenues and potential for profitability may be affected by the continuing efforts
of governments and third-party payers to contain or reduce the costs of healthcare through various
means. For example, in certain foreign markets the pricing of prescription pharmaceuticals is
subject to governmental control. In the United States, there has been, and we expect that there
will continue to be, a number of federal and state proposals to implement similar governmental
controls. We cannot be certain what legislative proposals will be adopted or what actions federal,
state or private payers for healthcare goods and services may take in response to any drug pricing
reform proposals or legislation. Such reforms may make it difficult to complete the development and
testing of AFREZZA and our other product candidates, and therefore may limit our ability to
generate revenues from sales of our product candidates and achieve profitability. Further, to the
extent that such reforms have a material adverse effect on the business, financial condition and
profitability of other companies that are prospective collaborators for some of our product
candidates, our ability to commercialize our product candidates under development may be adversely
affected.
In the United States and elsewhere, sales of prescription pharmaceuticals still depend in
large part on the availability of reimbursement to the consumer from third-party payers, such as
governmental and private insurance plans. Third-party payers are increasingly challenging the
prices charged for medical products and services. In addition, because each third-party payer
individually approves reimbursement, obtaining these approvals is a time-consuming and costly
process. We would be required to provide scientific and clinical support for the use of any product
to each third-party payer separately with no assurance that approval would be obtained. This
process could delay the market acceptance of any product and could have a negative effect on our
future revenues and operating results. Even if we succeed in bringing one or more products to
market, we cannot be certain that any such products would be considered cost-effective or that
reimbursement to the consumer would be available, in which case our business and results of
operations would be harmed and the market price of our common stock could decline.
If product liability claims are brought against us, we may incur significant liabilities and suffer
damage to our reputation.
The testing, manufacturing, marketing and sale of AFREZZA and our other product candidates
expose us to potential product liability claims. A product liability claim may result in
substantial judgments as well as consume significant financial and management resources and result
in adverse publicity, decreased demand for a product, injury to our reputation, withdrawal of
clinical trial volunteers and loss of revenues. We currently carry worldwide liability insurance in
the amount of $10 million. We believe these limits are reasonable to cover us from potential
damages arising from current and previous clinical trials of AFREZZA. In addition, we carry local
policies per trial in each country in which we conduct clinical trials that require us to carry
coverage based on local statutory requirements. We intend to obtain product liability coverage for
commercial sales in the future if AFREZZA is approved. However, we may not be able to obtain
insurance coverage that will be adequate to satisfy any liability that may arise, and because
insurance coverage in our industry can be very expensive and difficult to obtain, we cannot assure
you that we will be able to obtain sufficient coverage at an acceptable cost, if at all. If losses
from such claims exceed our liability insurance coverage, we may ourselves incur substantial
liabilities. If we are required to pay a product liability claim our business and results of
operations would be harmed and the market price of our common stock may decline.
If we lose any key employees or scientific advisors, our operations and our ability to execute our
business strategy could be materially harmed.
In order to commercialize our product candidates successfully, we will be required to expand
our work force, particularly in the areas of manufacturing, clinical trials management, regulatory
affairs, business development, and sales and marketing. These activities will require the addition
of new personnel, including management, and the development of additional expertise by existing
personnel. We face intense competition for qualified employees among companies in the biotechnology
and biopharmaceutical industries. Our success depends
upon our ability to attract, retain and motivate highly skilled employees. We may be unable to
attract and retain these individuals on acceptable terms, if at all.
The loss of the services of any principal member of our management and scientific staff could
significantly delay or prevent the achievement of our scientific and business objectives. All of
our employees are at will and we currently do not have employment agreements with any of the
principal members of our management or scientific staff, and we do not have key person life
insurance to cover the loss of any of these individuals. Replacing key employees may be difficult
and time-consuming because of the limited number of individuals in our industry with the skills and
experience required to develop, gain regulatory approval of and commercialize our product
candidates successfully.
We have relationships with scientific advisors at academic and other institutions to conduct
research or assist us in formulating our research, development or clinical strategy. These
scientific advisors are not our employees and may have commitments to, and other obligations with,
other entities that may limit their availability to us. We have limited control over the activities
of these scientific advisors and can generally expect these individuals to devote only limited time
to our activities. Failure of any of these persons to devote sufficient time and resources to our
programs could harm our business. In addition, these advisors are not prohibited from, and may have
arrangements with, other companies to assist those companies in developing technologies that may
compete with our product candidates.
If our Chairman and Chief Executive Officer is unable to devote sufficient time and attention to
our business, our operations and our ability to execute our business strategy could be materially
harmed.
Alfred Mann, our Chairman and Chief Executive Officer, is involved in many other business and
charitable activities. As a result, the time and attention Mr. Mann devotes to the operation of our
business varies, and he may not expend the same time or focus on our activities as other, similarly
situated chief executive officers. If Mr. Mann is unable to devote the time and attention necessary
to running our business, we may not be able to execute our business strategy and our business could
be materially harmed.
If our internal controls over financial reporting are not considered effective, our business and
stock price could be adversely affected.
Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our
internal controls over financial reporting as of the end of each fiscal year, and to include a
management report assessing the effectiveness of our internal controls over financial reporting in
our annual report on Form 10-K for that fiscal year. Section 404 also requires our independent
registered public accounting firm to attest to, and report on, our internal controls over financial
reporting.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not
expect that our internal controls over financial reporting will prevent all errors and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not
absolute, assurance that the control systems objectives will be met. Further, the design of a
control system must reflect the fact that there are resource constraints, and the benefits of
controls must be considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud involving a company have been, or will be, detected. The design of any
system of controls is based in part on certain assumptions about the likelihood of future events,
and we cannot assure you that any design will succeed in achieving its stated goals under all
potential future conditions. Over time, controls may become inadequate because of changes in
conditions or deterioration in the degree of compliance with policies or procedures. Because of the
inherent limitations in a cost-effective control system, misstatements due to error or fraud may
occur and not be detected. We cannot assure you that we or our independent registered public
accounting firm will not identify a material weakness in our internal controls in the future. A
material weakness in our internal controls over financial reporting would require management and
our independent registered public accounting firm to evaluate our internal controls as ineffective.
If our internal controls over financial reporting are not considered effective, we may experience a
loss of public confidence, which could have an adverse effect on our business and on the market
price of our common stock.
RISKS RELATED TO REGULATORY APPROVALS
Our product candidates must undergo rigorous nonclinical and clinical testing and we must obtain
regulatory approvals, which could be costly and time-consuming and subject us to unanticipated
delays or prevent us from marketing any products.
Our research and development activities, as well as the manufacturing and marketing of our
product candidates, including AFREZZA, are subject to regulation, including regulation for safety,
efficacy and quality, by the FDA in the United States and comparable authorities in other
countries. FDA regulations and the regulations of comparable foreign regulatory authorities are
wide-ranging and govern, among other things:
| product design, development, manufacture and testing; | ||
| product labeling; | ||
| product storage and shipping; | ||
| pre-market clearance or approval; | ||
| advertising and promotion; and | ||
| product sales and distribution. |
Clinical testing can be costly and take many years, and the outcome is uncertain and
susceptible to varying interpretations. We cannot be certain if or when the FDA might request
additional studies, under what conditions such studies might be requested, or what the size or
length of any such studies might be. The clinical trials of our product candidates may not be
completed on schedule, the FDA or foreign regulatory agencies may order us to stop or modify our
research, or these agencies may not ultimately approve any of our product candidates for commercial
sale. The data collected from our clinical trials may not be sufficient to support regulatory
approval of our various product candidates, including AFREZZA. Even if we believe the data
collected from our clinical trials are sufficient, the FDA has substantial discretion in the
approval process and may disagree with our interpretation of the data. Our failure to adequately
demonstrate the safety and efficacy of any of our product candidates would delay or prevent
regulatory approval of our product candidates, which could prevent us from achieving profitability.
The requirements governing the conduct of clinical trials and manufacturing and marketing of
our product candidates, including AFREZZA, outside the United States vary widely from country to
country. Foreign approvals may take longer to obtain than FDA approvals and can require, among
other things, additional testing and different clinical trial designs. Foreign regulatory approval
processes include essentially all of the risks associated with the FDA approval processes. Some of
those agencies also must approve prices of the products. Approval of a product by the FDA does not
ensure approval of the same product by the health authorities of other countries. In addition,
changes in regulatory policy in the United States or in foreign countries for product approval
during the period of product development and regulatory agency review of each submitted new
application may cause delays or rejections.
The process of obtaining FDA and other required regulatory approvals, including foreign
approvals, is expensive, often takes many years and can vary substantially based upon the type,
complexity and novelty of the products involved. We are not aware of any precedent for the
successful commercialization of products based on our technology. In January 2006, the FDA approved
the first pulmonary insulin product, Exubera. This approval has had an impact on and,
notwithstanding the voluntary withdrawal of the product from the market by its manufacturer, could
still impact the development and registration of AFREZZA in different ways. For example, Exubera
may be used as a reference for safety and efficacy evaluations of AFREZZA, and the approval
standards set for Exubera may be applied to other products that follow, including AFREZZA.
In March 2009, we submitted an NDA for AFREZZA. The FDA has advised us that it will regulate
AFREZZA as a combination product because of the complex nature of the system that includes the
combination
of a new drug (AFREZZA) and a new medical device (the AFREZZA inhaler used to administer the
insulin). The FDAs review of our NDA for AFREZZA involves several separate review groups of the
FDA including: (1) the Metabolic and Endocrine Drug Products Division; (2) the Pulmonary Drug
Products Division; and (3) the Center for Devices and Radiological Health, which reviews medical
devices. The Metabolic and Endocrine Drug Products Division is the lead group and obtains
consulting reviews from the other two FDA groups. We can make no assurances at this time about what
impact FDA review by multiple groups will have on the approvability of our product.
In March 2010, we received a Complete Response letter regarding this NDA from the FDA. A
Complete Response letter is issued by the FDAs Center for Drug Evaluation and Research when the
review of a submitted file is completed and questions remain that preclude the approval of the NDA
in its current form. In July 2010, the FDA accepted our reply to the Complete Response letter and
set a target action date of December 29, 2010. There can be no assurance that the FDA will find our
proposed approach for addressing its questions acceptable. The FDA could also request that we
conduct additional clinical trials to provide sufficient data for approval of the NDA. There can be
no assurance that we will obtain approval of the NDA in a timely manner or at all.
Also, questions that have been raised about the safety of marketed drugs generally, including
pertaining to the lack of adequate labeling, may result in increased cautiousness by the FDA in
reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in
significant delays in obtaining regulatory approvals. Such regulatory considerations may also
result in the imposition of more restrictive drug labeling or marketing requirements as conditions
of approval, which may significantly affect the marketability of our drug products. FDA review of
AFREZZA as a combination product may lengthen the product development and regulatory approval
process, increase our development costs and delay or prevent the commercialization of AFREZZA.
We are developing AFREZZA as a new treatment for diabetes utilizing unique, proprietary
components. As a combination product, any changes to either the AFREZZA inhaler, or AFREZZA,
including new suppliers, could possibly result in FDA requirements to repeat certain clinical
studies. For example, we plan to launch AFREZZA with our next-generation inhaler rather than the
device that was used in pivotal clinical studies, and in our July 2010 reply to the FDAs Complete
Response letter, we submitted information on the comparability of our next-generation inhaler to
the device that was used in pivotal clinical studies. As a result of our change to our
next-generation inhaler, the FDA could yet require us to undertake additional clinical trials and
other studies, which could significantly delay the development and commercialization of AFREZZA.
Our product candidates that are currently in development for the treatment of cancer also face
similar obstacles and costs.
We also must obtain final approval from the FDA for the trade name of our product. In
September 2009, we proposed AFREZZA as a trade name, which the FDA found conditionally acceptable
in December 2009.
We have only limited experience in filing and pursuing applications necessary to gain regulatory
approvals, which may impede our ability to obtain timely approvals from the FDA or foreign
regulatory agencies, if at all.
We will not be able to commercialize AFREZZA or any other product candidates until we have
obtained regulatory approval. Until we prepared and submitted our NDA for AFREZZA, we had no
experience as a company in late-stage regulatory filings, such as preparing and submitting NDAs,
which may place us at risk of delays, overspending and human resources inefficiencies. Any delay in
obtaining, or inability to obtain, regulatory approval could harm our business.
If we do not comply with regulatory requirements at any stage, whether before or after marketing
approval is obtained, we may be subject to criminal prosecution, fined or forced to remove a
product from the market or experience other adverse consequences, including restrictions or delays
in obtaining regulatory marketing approval.
Even if we comply with regulatory requirements, we may not be able to obtain the labeling
claims necessary or desirable for product promotion. We may also be required to undertake
post-marketing trials. In addition, if we or other parties identify adverse effects after any of
our products are on the market, or if manufacturing problems occur, regulatory approval may be
withdrawn and a reformulation of our products,
additional clinical trials, changes in labeling of, or indications of use for, our products
and/or additional marketing applications may be required. If we encounter any of the foregoing
problems, our business and results of operations will be harmed and the market price of our common
stock may decline.
Even if we obtain regulatory approval for our product candidates, such approval may be limited and
we will be subject to stringent, ongoing government regulation.
Even if regulatory authorities approve any of our product candidates, they could approve less
than the full scope of uses or labeling that we seek or otherwise require special warnings or other
restrictions on use or marketing or could require potentially costly post-marketing follow-up
clinical trials. Regulatory authorities may limit the segments of the diabetes population to which
we or others may market AFREZZA or limit the target population for our other product candidates.
Based on currently available clinical studies, we believe that AFREZZA may have certain advantages
over currently approved insulin products including its approximation of the natural early insulin
secretion normally seen in healthy individuals following the beginning of a meal. Nonetheless,
there are no assurances that these or any other advantages of AFREZZA will be agreed to by the FDA
or otherwise included in product labeling or advertising and, as a result, AFREZZA may not have our
expected competitive advantages when compared to other insulin products.
The manufacture, marketing and sale of any of our product candidates will be subject to
stringent and ongoing government regulation. The FDA may also withdraw product approvals if
problems concerning safety or efficacy of a product occurs following approval. We cannot be sure
that FDA and United States Congressional initiatives pertaining to ensuring the safety of marketed
drugs or other developments pertaining to the pharmaceutical industry will not adversely affect our
operations.
We also are required to register our establishments and list our products with the FDA and
certain state agencies. We and any third-party manufacturers or suppliers must continually adhere
to federal regulations setting forth requirements, known as cGMP (for drugs) and QSR (for medical
devices), and their foreign equivalents, which are enforced by the FDA and other national
regulatory bodies through their facilities inspection programs. If our facilities, or the
facilities of our manufacturers or suppliers, cannot pass a preapproval plant inspection, the FDA
will not approve the marketing of our product candidates. In complying with cGMP and foreign
regulatory requirements, we and any of our potential third-party manufacturers or suppliers will be
obligated to expend time, money and effort in production, record-keeping and quality control to
ensure that our products meet applicable specifications and other requirements. QSR requirements
also impose extensive testing, control and documentation requirements. State regulatory agencies
and the regulatory agencies of other countries have similar requirements. In addition, we will be
required to comply with regulatory requirements of the FDA, state regulatory agencies and the
regulatory agencies of other countries concerning the reporting of adverse events and device
malfunctions, corrections and removals (e.g., recalls), promotion and advertising and general
prohibitions against the manufacture and distribution of adulterated and misbranded devices.
Failure to comply with these regulatory requirements could result in civil fines, product seizures,
injunctions and/or criminal prosecution of responsible individuals and us. Any such actions would
have a material adverse effect on our business and results of operations.
Our insulin supplier does not yet supply human recombinant insulin for an FDA-approved product.
Our insulin supplier for purposes of the AFREZZA NDA sells its product outside of the United
States. The FDA has inspected this supplier and found it to be acceptable. If we were required to
find a new or additional supplier of insulin, we would be required to evaluate the new suppliers
ability to provide insulin that meets our specifications and quality requirements, which would
require significant time and expense and could delay the manufacturing and future commercialization
of AFREZZA. We also depend on suppliers for other materials that comprise AFREZZA, including our
AFREZZA inhaler and cartridges. Each device supplier must comply with relevant regulatory
requirements including QSR and is subject to inspection by the FDA. There can be no assurance, in
the conduct of an inspection of any of our suppliers, that the agency would find that the supplier
substantially complies with the QSR or cGMP requirements, where applicable. If we or any potential
third-party manufacturer or supplier fails to comply with these requirements or comparable
requirements in foreign countries, regulatory authorities may subject us to regulatory action,
including criminal prosecutions, fines and suspension of the manufacture of our products.
Reports of side effects or safety concerns in related technology fields or in other companies
clinical trials could delay or prevent us from obtaining regulatory approval or negatively impact
public perception of our product candidates.
At present, there are a number of clinical trials being conducted by us and other
pharmaceutical companies involving insulin delivery systems. If we discover that AFREZZA is
associated with a significantly increased frequency of adverse events, or if other pharmaceutical
companies announce that they observed frequent adverse events in their trials involving the
pulmonary delivery of insulin, we could encounter delays in the timing of our clinical trials or
difficulties in obtaining approval of AFREZZA. As well, the public perception of AFREZZA might be
adversely affected, which could harm our business and results of operations and cause the market
price of our common stock to decline, even if the concern relates to another companys products or
product candidates.
There are also a number of clinical trials being conducted by other pharmaceutical companies
involving compounds similar to, or competitive with, our other product candidates. Adverse results
reported by these other companies in their clinical trials could delay or prevent us from obtaining
regulatory approval or negatively impact public perception of our product candidates, which could
harm our business and results of operations and cause the market price of our common stock to
decline.
RISKS RELATED TO INTELLECTUAL PROPERTY
If we are unable to protect our proprietary rights, we may not be able to compete effectively, or
operate profitably.
Our commercial success depends, in large part, on our ability to obtain and maintain
intellectual property protection for our technology. Our ability to do so will depend on, among
other things, complex legal and factual questions, and it should be noted that the standards
regarding intellectual property rights in our fields are still evolving. We attempt to protect our
proprietary technology through a combination of patents, trade secrets and confidentiality
agreements. We own a number of domestic and international patents, have a number of domestic and
international patent applications pending and have licenses to additional patents. We cannot assure
you that our patents and licenses will successfully preclude others from using our technologies,
and we could incur substantial costs in seeking enforcement of our proprietary rights against
infringement. Even if issued, the patents may not give us an advantage over competitors with
similar alternative technologies.
Moreover, the issuance of a patent is not conclusive as to its validity or enforceability and
it is uncertain how much protection, if any, will be afforded by our patents. A third party may
challenge the validity or enforceability of a patent after its issuance by various proceedings such
as oppositions in foreign jurisdictions or re-examinations in the United States. If we attempt to
enforce our patents, they may be challenged in court where they could be held invalid,
unenforceable, or have their breadth narrowed to an extent that would destroy their value.
We also rely on unpatented technology, trade secrets, know-how and confidentiality agreements.
We require our officers, employees, consultants and advisors to execute proprietary information and
invention and assignment agreements upon commencement of their relationships with us. We also
execute confidentiality agreements with outside collaborators. There can be no assurance, however,
that these agreements will provide meaningful protection for our inventions, trade secrets,
know-how or other proprietary information in the event of unauthorized use or disclosure of such
information. If any trade secret, know-how or other technology not protected by a patent were to be
disclosed to or independently developed by a competitor, our business, results of operations and
financial condition could be adversely affected.
If we become involved in lawsuits to protect or enforce our patents or the patents of our
collaborators or licensors, we would be required to devote substantial time and resources to
prosecute or defend such proceedings.
Competitors may infringe our patents or the patents of our collaborators or licensors. To
counter infringement or unauthorized use, we may be required to file infringement claims, which can
be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide
that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover its technology. A court
may also decide to award us a royalty from an infringing party instead of issuing an injunction
against the infringing activity. An adverse determination of any litigation or defense
proceedings could put one or more of our patents at risk of being invalidated or interpreted
narrowly and could put our patent applications at risk of not issuing.
Interference proceedings brought by the U.S. Patent and Trademark Office may be necessary to
determine the priority of inventions with respect to our patent applications or those of our
collaborators or licensors. Litigation or interference proceedings may fail and, even if
successful, may result in substantial costs and be a distraction to our management. We may not be
able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary
rights, particularly in countries where the laws may not protect such rights as fully as in the
United States. We may not prevail in any litigation or interference proceeding in which we are
involved. Even if we do prevail, these proceedings can be very expensive and distract our
management.
Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. In addition, during the course of this
kind of litigation, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, the market price of our common stock may decline.
If our technologies conflict with the proprietary rights of others, we may incur substantial costs
as a result of litigation or other proceedings and we could face substantial monetary damages and
be precluded from commercializing our products, which would materially harm our business.
Over the past three decades the number of patents issued to biotechnology companies has
expanded dramatically. As a result it is not always clear to industry participants, including us,
which patents cover the multitude of biotechnology product types. Ultimately, the courts must
determine the scope of coverage afforded by a patent and the courts do not always arrive at uniform
conclusions.
A patent owner may claim that we are making, using, selling or offering for sale an invention
covered by the owners patents and may go to court to stop us from engaging in such activities.
Such litigation is not uncommon in our industry.
Patent lawsuits can be expensive and would consume time and other resources. There is a risk
that a court would decide that we are infringing a third partys patents and would order us to stop
the activities covered by the patents, including the commercialization of our products. In
addition, there is a risk that we would have to pay the other party damages for having violated the
other partys patents (which damages may be increased, as well as attorneys fees ordered paid, if
infringement is found to be willful), or that we will be required to obtain a license from the
other party in order to continue to commercialize the affected products, or to design our products
in a manner that does not infringe a valid patent. We may not prevail in any legal action, and a
required license under the patent may not be available on acceptable terms or at all, requiring
cessation of activities that were found to infringe a valid patent. We also may not be able to
develop a non-infringing product design on commercially reasonable terms, or at all.
Moreover, certain components of AFREZZA and/or our cancer vaccines may be manufactured outside
the United States and imported into the United States. As such, third parties could file complaints
under 19 U.S.C. Section 337(a)(1)(B), or a 337 action, with the International Trade Commission, or
the ITC. A 337 action can be expensive and would consume time and other resources. There is a risk
that the ITC would decide that we are infringing a third partys patents and either enjoin us from
importing the infringing products or parts thereof into the United States or set a bond in an
amount that the ITC considers would offset our competitive advantage from the continued importation
during the statutory review period. The bond could be up to 100% of the value of the patented
products. We may not prevail in any legal action, and a required license under the patent may not
be available on acceptable terms, or at all, resulting in a permanent injunction preventing any
further importation of the infringing products or parts thereof into the United States. We also may
not be able to develop a non-infringing product design on commercially reasonable terms, or at all.
Although we own a number of domestic and foreign patents and patent applications relating to
AFREZZA and cancer vaccine products under development, we have identified certain third-party
patents having claims relating to pulmonary insulin delivery that may trigger an allegation of
infringement upon the commercial
manufacture and sale of AFREZZA as well as third-party patents disclosing methods of use and
compositions of matter related to cancer vaccines that also may trigger an allegation of
infringement upon the commercial manufacture and sale of our cancer immunotherapy. If a court were
to determine that our insulin products or cancer therapies were infringing any of these patent
rights, we would have to establish with the court that these patents were invalid or unenforceable
in order to avoid legal liability for infringement of these patents. However, proving patent
invalidity or unenforceability can be difficult because issued patents are presumed valid.
Therefore, in the event that we are unable to prevail in an infringement or invalidity action we
will have to either acquire the third-party patents outright or seek a royalty-bearing license.
Royalty-bearing licenses effectively increase production costs and therefore may materially affect
product profitability. Furthermore, should the patent holder refuse to either assign or license us
the infringed patents, it may be necessary to cease manufacturing the product entirely and/or
design around the patents, if possible. In either event, our business would be harmed and our
profitability could be materially adversely impacted.
Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. In addition, during the course of this
kind of litigation, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, the market price of our common stock may decline.
In addition, patent litigation may divert the attention of key personnel and we may not have
sufficient resources to bring these actions to a successful conclusion. At the same time, some of
our competitors may be able to sustain the costs of complex patent litigation more effectively than
we can because they have substantially greater resources. An adverse determination in a judicial or
administrative proceeding or failure to obtain necessary licenses could prevent us from
manufacturing and selling our products or result in substantial monetary damages, which would
adversely affect our business and results of operations and cause the market price of our common
stock to decline.
We may not obtain trademark registrations for our potential trade names.
We have not selected trade names for some of our product candidates; therefore, we have not
filed trademark registrations for our potential trade names for our product candidates in all
jurisdictions, nor can we assure that we will be granted registration of those potential trade
names for which we have filed. Although we intend to defend any opposition to our trademark
registrations, no assurance can be given that any of our trademarks will be registered in the
United States or elsewhere or that the use of any of our trademarks will confer a competitive
advantage in the marketplace. Furthermore, even if we are successful in our trademark
registrations, the FDA has its own process for drug nomenclature and its own views concerning
appropriate proprietary names. It also has the power, even after granting market approval, to
request a company to reconsider the name for a product because of evidence of confusion in the
marketplace. We cannot assure you that the FDA or any other regulatory authority will approve of
any of our trademarks or will not request reconsideration of one of our trademarks at some time in
the future.
RISKS RELATED TO OUR COMMON STOCK
Our stock price is volatile.
The stock market, particularly in recent years, has experienced significant volatility
particularly with respect to pharmaceutical and biotechnology stocks, and this trend may continue.
The volatility of pharmaceutical and biotechnology stocks often does not relate to the operating
performance of the companies represented by the stock. Our business and the market price of our
common stock may be influenced by a large variety of factors, including:
| the progress and results of our clinical trials; | ||
| general economic, political or stock market conditions; |
| legislative developments; | ||
| announcements by us or our competitors concerning clinical trial results, acquisitions, strategic alliances, technological innovations, newly approved commercial products, product discontinuations, or other developments; | ||
| the availability of critical materials used in developing and manufacturing AFREZZA or other product candidates; | ||
| developments or disputes concerning our patents or proprietary rights; | ||
| the expense and time associated with, and the extent of our ultimate success in, securing regulatory approvals; | ||
| announcements by us concerning our financial condition or operating performance; | ||
| changes in securities analysts estimates of our financial condition or operating performance; | ||
| general market conditions and fluctuations for emerging growth and pharmaceutical market sectors; | ||
| the issuance and sale of our common stock pursuant to the Seaside purchase agreement and the Mann purchase agreement over the terms of these agreements; | ||
| sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders; | ||
| the existence of, and the issuance of shares of our common stock pursuant to, the share lending agreement and the short sales of our common stock effected in connection with the recently-completed sale of our 5.75% convertible notes due 2015; and | ||
| discussion of AFREZZA, our other product candidates, competitors products, or our stock price by the financial and scientific press, the healthcare community and online investor communities such as chat rooms. In particular, statements about us and our investigational products that appear on interactive websites that permit users to generate content anonymously or under a pseudonym may be difficult to verify and statements attributed to company officials may, in fact, have originated elsewhere. |
Any of these risks, as well as other factors, could cause the market price of our common stock to
decline.
If other biotechnology and biopharmaceutical companies or the securities markets in general
encounter problems, the market price of our common stock could be adversely affected.
Public companies in general and companies included on the Nasdaq Global Market in particular
have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of those companies. There has been particular
volatility in the market prices of securities of biotechnology and other life sciences companies,
and the market prices of these companies have often fluctuated because of problems or successes in
a given market segment or because investor interest has shifted to other segments. These broad
market and industry factors may cause the market price of our common stock to decline, regardless
of our operating performance. We have no control over this volatility and can only focus our
efforts on our own operations, and even these may be affected due to the state of the capital
markets.
In the past, following periods of large price declines in the public market price of a
companys securities, securities class action litigation has often been initiated against that
company. Litigation of this type could result in substantial costs and diversion of managements
attention and resources, which would hurt our business. Any adverse determination in litigation
could also subject us to significant liabilities.
Our Chairman and Chief Executive Officer and principal stockholder can individually control our
direction and policies, and his interests may be adverse to the interests of our other
stockholders. After his death, his stock will be left to his funding foundations for distribution
to various charities, and we cannot assure you of the manner in which those entities will manage
their holdings.
At July 23, 2010, Mr. Mann beneficially owned approximately 42.1% of our outstanding shares of
capital stock. After giving effect to our recently-completed issuance of 9,000,000 shares of our
common stock, at July 23, 2010 Mr. Mann would have beneficially owned approximately 39.0% of our
outstanding shares of capital stock. We believe members of Mr. Manns family beneficially owned
approximately an additional 1% of our outstanding shares of common stock, although Mr. Mann does
not have voting or investment power with respect to these shares. By virtue of his holdings, Mr.
Mann can and will continue to be able to effectively control the election of the members of our
board of directors, our management and our affairs and prevent corporate transactions such as
mergers, consolidations or the sale of all or substantially all of our assets that may be favorable
from our standpoint or that of our other stockholders or cause a transaction that we or our other
stockholders may view as unfavorable.
Subject to compliance with United States federal and state securities laws, and lockup
restrictions in connection with the recently-completed sale of our 5.75% convertible notes due
2015, Mr. Mann is free to sell the shares of our stock he holds at any time. Upon his death, we
have been advised by Mr. Mann that his shares of our capital stock will be left to the Alfred E.
Mann Medical Research Organization, or AEMMRO, and AEM Foundation for Biomedical Engineering, or
AEMFBE, not-for-profit medical research foundations that serve as funding organizations for Mr.
Manns various charities, including the Alfred Mann Foundation, or AMF, and the Alfred Mann
Institutes at the University of Southern California, the Technion-Israel Institute of Technology,
and Purdue University, and that may serve as funding organizations for any other charities that he
may establish. The AEMMRO is a membership foundation consisting of six members, including Mr. Mann,
his wife, three of his children and Dr. Joseph Schulman, the chief scientist of the AEMFBE. The
AEMFBE is a membership foundation consisting of five members, including Mr. Mann, his wife, and the
same three of his children. Although we understand that the members of AEMMRO and AEMFBE have been
advised of Mr. Manns objectives for these foundations, once Mr. Manns shares of our capital stock
become the property of the foundations, we cannot assure you as to how those shares will be
distributed or how they will be voted.
The future sale of our common stock or the conversion of our senior convertible notes into common
stock could negatively affect our stock price.
As of July 23, 2010, we had approximately 113,760,415 shares of common stock outstanding.
Substantially all of these shares are available for public sale, subject in some cases to volume
and other limitations or delivery of a prospectus. If our common stockholders sell substantial
amounts of common stock in the public market, or the market perceives that such sales may occur,
the market price of our common stock may decline. Likewise the issuance of additional shares of our
common stock upon the conversion of some or all of our senior convertible notes could adversely
affect the trading price of our common stock. In addition, the existence of these notes may
encourage short selling of our common stock by market participants. Furthermore, if we were to
include in a company-initiated registration statement shares held by our stockholders pursuant to
the exercise of their registration rights, the sale of those shares could impair our ability to
raise needed capital by depressing the price at which we could sell our common stock.
On August 10, 2010, we entered into the Seaside purchase agreement and the Mann purchase
agreement, which together provide for the sale and issuance by us of up to 36,400,000 shares of our
common stock over a period of approximately 50 weeks. The future issuance of shares of our common
stock pursuant to these two agreements, or the expectation that these issuances will occur, may
further depress the price of our common stock.
In addition, we will need to raise substantial additional capital in the future to fund our
operations. If we raise additional funds by issuing equity securities or additional convertible
debt, the market price of our common stock may decline and our existing stockholders may experience
significant dilution.
We have reserved for future issuance substantially all of our authorized but unissued shares of
common stock, which may impair our ability to conduct future financing and other transactions.
Our certificate of incorporation currently authorizes us to issue up to 200,000,000 shares of
common stock and 10,000,000 shares of preferred stock. As of June 30, 2010, we had a total of
86,325,779 shares of common stock that were authorized but unissued. In August 2010, we issued
9,000,000 shares pursuant to a share lending agreement with Bank of America, N.A. and we have
reserved substantially all of our remaining authorized but unissued shares for future issuance
pursuant to outstanding equity awards, our equity plans, our 3.75% senior convertible notes due
2013, our 5.75% senior convertible notes due 2015 and our common stock purchase agreements with
Seaside 88 and The Mann Group. As a result, our ability to issue shares of common stock other than
pursuant to existing arrangements will be limited until such time, if ever, that we are able to
amend our certificate of incorporation to further increase our authorized shares of common stock or
shares currently reserved for issuance otherwise become available (for example, due to the
termination of the underlying agreement to issue the shares).
If we are unable to enter into new arrangements to issue shares of our common stock or
securities convertible or exercisable into shares of our common stock, our ability to complete
equity-based financings or other transactions that involve the potential issuance of our common
stock or securities convertible or exercisable into our common stock, will be limited. In lieu of
issuing common stock or securities convertible into our common stock in any future equity financing
transactions, we may need to issue some or all of our authorized but unissued shares of preferred
stock, which would likely have superior rights, preferences and privileges to those of our common
stock, or we may need to issue debt that is not convertible into shares of our common stock, which
may require us to grant security interests in our assets and property and/or impose covenants upon
us that restrict our business. If we are unable to issue additional shares of common stock or
securities convertible or exercisable into our common stock, our ability to enter into strategic
transactions such as acquisitions of companies or technologies, may also be limited. If we propose
to amend our certificate of incorporation to increase our authorized shares of common stock, such a
proposal would require the approval by the holders of a majority of our outstanding shares of
common stock, and we cannot assure you that such a proposal would be adopted. If we are unable to
complete financing, strategic or other transactions due to our inability to issue additional shares
of common stock or securities convertible or exercisable into our common stock, our financial
condition and business prospects may be materially harmed.
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition
of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our
stockholders to replace or remove our current management.
We are incorporated in Delaware. Certain anti-takeover provisions under Delaware law and in
our certificate of incorporation and amended and restated bylaws, as currently in effect, may make
a change of control of our company more difficult, even if a change in control would be beneficial
to our stockholders. Our anti-takeover provisions include provisions such as a prohibition on
stockholder actions by written consent, the authority of our board of directors to issue preferred
stock without stockholder approval, and supermajority voting requirements for specified actions. In
addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law,
which generally prohibits stockholders owning 15% or more of our outstanding voting stock from
merging or combining with us in certain circumstances. These provisions may delay or prevent an
acquisition of us, even if the acquisition may be considered beneficial by some of our
stockholders. In addition, they may frustrate or prevent any attempts by our stockholders to
replace or remove our current management by making it more difficult for stockholders to replace
members of our board of directors, which is responsible for appointing the members of our
management.
Because we do not expect to pay dividends in the foreseeable future, you must rely on stock
appreciation for any return on your investment.
We have paid no cash dividends on any of our capital stock to date, and we currently intend to
retain our future earnings, if any, to fund the development and growth of our business. As a
result, we do not expect to pay any cash dividends in the foreseeable future, and payment of cash
dividends, if any, will also depend on our financial condition, results of operations, capital
requirements and other factors and will be at the discretion of our board of directors.
Furthermore, we may in the future become subject to contractual restrictions on, or prohibitions
against, the payment of dividends. Accordingly, the success of your investment in our common stock
will likely depend
entirely upon any future appreciation. There is no guarantee that our common stock will
appreciate or maintain its current price. You could lose the entire value of your investment in our
common stock.
Description of Capital Stock
Our authorized capital stock consists of 200,000,000 shares of common stock, $0.01 par value,
and 10,000,000 shares of preferred stock, $0.01 par value. As of June 30, 2010, there were
113,674,221 shares of common stock outstanding and no shares of preferred stock outstanding.
Voting Rights
Each holder of our common stock is entitled to one vote for each share on all matters
submitted to a vote of our stockholders, including the election of our directors. Under our
certificate of incorporation and bylaws, our stockholders will not have cumulative voting rights.
Accordingly, the holders of a majority of our outstanding shares of common stock entitled to vote
in any election of directors can elect all of the directors standing for election, if they should
so choose.
Dividends
Subject to preferences that may be applicable to any outstanding shares of our preferred
stock, holders of our common stock are entitled to receive ratably any dividends our board of
directors declares out of funds legally available for that purpose.
Liquidation, Dissolution or Winding Up
If we liquidate, dissolve or wind up, the holders of our common stock are entitled to
share ratably in all assets legally available for distribution to our stockholders after the
payment of all of our debts and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any outstanding shares of our preferred stock.
Rights and Preferences
Our common stock has no preemptive, conversion or subscription rights. There are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and
privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of any outstanding shares of our of preferred stock, which we may designate
and issue in the future.
Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and
Bylaws
Delaware takeover statute
We are subject to Section 203 of the Delaware General Corporation Law, or DGCL, which
regulates acquisitions of some Delaware corporations. In general, Section 203 prohibits, with some
exceptions, a publicly held Delaware corporation from engaging in a business combination with an
interested stockholder for a period of three years following the date of the transaction in which
the person became an interested stockholder, unless:
| the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other transaction; | ||
| upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
| on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business combination at an annual or special meeting of stockholders by the affirmative vote of at least 662/3% of the outstanding stock of the corporation not owned by the interested stockholder. |
Section 203 of the DGCL generally defines a business combination to include any of the
following:
| any merger or consolidation involving the corporation and the interested stockholder; | ||
| any sale, transfer, pledge or other disposition of 10% or more of the corporations assets or outstanding stock involving the interested stockholder; | ||
| in general, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder; | ||
| any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or | ||
| the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
In general, Section 203 defines an interested stockholder as any person who, together
with the persons affiliates and associates, owns, or within three years prior to the determination
of interested stockholder status did own, 15% or more of a corporations voting stock.
Section 203 of the DGCL could depress our stock price and delay, discourage or prohibit
transactions not approved in advance by our board of directors, such as takeover attempts that
might otherwise involve the payment to our stockholders of a premium over the market price of our
common stock.
Certificate of incorporation and bylaw provisions
Our certificate of incorporation and bylaws include a number of provisions that may have
the effect of deterring hostile takeovers or delaying or preventing changes in our control or our
management, including, but not limited to the following:
| Our board of directors can issue up to 10,000,000 shares of preferred stock with any rights or preferences, including the right to approve or not approve an acquisition or other change in our control. | ||
| Our certificate of incorporation and bylaws provide that all stockholder actions must be effected at a duly called meeting of holders and not by written consent. | ||
| Our bylaws provide that special meetings of the stockholders may be called only by the Chairman of our board of directors, by our Chief Executive Officer, by our board of directors upon a resolution adopted by a majority of the total number of authorized directors or, under certain limited circumstances, by the holders of at least 5% of our outstanding voting stock. | ||
| Our bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide timely |
notice in writing and also specify requirements as to the form and content of a stockholders notice. These provisions may delay or preclude stockholders from bringing matters before a meeting of our stockholders or from making nominations for directors at a meeting of stockholders, which could delay or deter takeover attempts or changes in our management. | |||
| Our certificate of incorporation provides that, subject to the rights of the holders of any outstanding series of preferred stock, all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum. In addition, our certificate of incorporation provides that our board of directors may fix the number of directors by resolution. | ||
| Our certificate of incorporation does not provide for cumulative voting for directors. The absence of cumulative voting may make it more difficult for stockholders who own an aggregate of less than a majority of our voting stock to elect any directors to our board of directors. |
These and other provisions contained in our certificate of incorporation and bylaws are
expected to discourage coercive takeover practices and inadequate takeover bids. These provisions
are also designed to encourage persons seeking to acquire control of us to first negotiate with our
board of directors. However, these provisions could delay or discourage transactions involving an
actual or potential change in control of us or our management, including transactions in which our
stockholders might otherwise receive a premium for their shares over market price of our stock and
may limit the ability of stockholders to remove our current management or approve transactions that
our stockholders may deem to be in their best interests and, therefore, could adversely affect the
price of our common stock.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is BNY Mellon Shareowner Services,
LLC. Its address is 400 South Hope Street, Suite 400, Los Angeles, California 90071.